Name (Synonyms) | Correlation | |
---|---|---|
drug678 | Covid-19 Rapid Test Kit (RAPG-COV-019) Wiki | 1.00 |
Name (Synonyms) | Correlation | |
---|---|---|
D008173 | Lung Diseases, Obstructive NIH | 0.33 |
D008171 | Lung Diseases, NIH | 0.26 |
D002318 | Cardiovascular Diseases NIH | 0.21 |
D011024 | Pneumonia, Viral NIH | 0.13 |
D011014 | Pneumonia NIH | 0.06 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006536 | Pulmonary obstruction HPO | 0.33 |
HP:0002088 | Abnormal lung morphology HPO | 0.26 |
HP:0001626 | Abnormality of the cardiovascular system HPO | 0.21 |
HP:0002090 | Pneumonia HPO | 0.06 |
There is one clinical trial.
Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibody tests to help develop methodologies which provide fast and accurate results. Infection with coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing for COVID-19 is crucial to understand who is infected and therefore a risk to others by spreading the infection. The tests that are currently being investigated by RRI include: A. The RAPG-COV-019 kit, a small testing cartridge developed by Biopanda Reagents which detects whether an individual has been infected by the coronavirus (SARS-CoV-2) by using a spot of the person's blood and displays these results in 10 minutes. B. An already established laboratory test that detects SARS-CoV-2 by a process known as polymerase chain reaction (PCR). This test is accurate but expensive, time consuming and requires highly trained staff and laboratory facilities. C. Development of a quantitative laboratory reference test for antibodies (IgG) against the novel SARS-CoV-2 virus. The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) in their workforce, as well as their families and visitors to their site. The RAPG-COV-019 kit can be used by non-experts and provides results within minutes, and would allow rapid, inexpensive diagnosis of coronavirus (SARS-CoV-2) infection. The results will enable determination of whether the RAPG-COV-019 kit can make a reliable diagnosis. Collecting this data also allows the gathering of epidemiological data on SARS-CoV-2 including incidence, prevalence and information on asymptomatic carriers. Furthermore, identifying individuals that are infected with SARS-CoV-2 has great potential to improve health outcomes by allowing infected individuals to seek the correct medical treatment as well as self-isolate and reduce transmission.
Description: Identification of trial participants who are asymptomatic carriers of SARS-CoV-2 by comparing the results of a blood finger stick test and reference laboratory tests to PCR testing for acute infection
Measure: Identification of asymptomatic carriers of SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Validation the sensitivity, specificity and reproducibility of the RAPG-COV-019 kit to detect SARS-CoV-2 infection. To help develop a quantitative laboratory reference test for antibodies (IgG) to gain an understanding of quantity of antibodies that people develop and how these decrease over time.
Measure: Validation of the ability of the immunoassay kit to detect antibodies to SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Determination of the understanding of the quantity of IgG antibodies developed as a response to SARS-CoV-2 infection, and how these antibody levels decrease over time. Antibody titres will be measured in infected individuals, over multiple days and correlated with disease parameters. This will facilitate the development of a quantitative laboratory reference test for IgG antibodies
Measure: Development of a quantitative laboratory reference test for the measurement of SARS-CoV-2 Time: Through study completion, estimated 12 weeksDescription: Execution of an epidemiological study on SARS-CoV-2 carriage and transmission in a well-controlled clinical environment with extensive measures in place to prevent viral transmission
Measure: Exploration of SARS-CoV-2 epidemiology Time: Through study completion, estimated 12 weeks